NURESCA Trademark

Trademark Overview

On Wednesday, February 6, 2002, a trademark application was filed for NURESCA with the United States Patent and Trademark Office. The USPTO has given the NURESCA trademark a serial number of 78107171. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, July 1, 2011. This trademark is owned by Pfizer Inc.. The NURESCA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of [ cardiovascular disease, ] infectious diseases, and immunological, viral disorders

General Information

Serial Number78107171
Word MarkNURESCA
Filing DateWednesday, February 6, 2002
Status710 - CANCELLED - SECTION 8
Status DateFriday, July 1, 2011
Registration Number2907172
Registration DateTuesday, November 30, 2004
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, July 30, 2002

Trademark Statements

Certificate of Correction for RegistrationIn the statement, column 1 lines 5 and 6, "CARDIOVASCULAR DISEASE" should be deleted.
Goods and ServicesPharmaceutical preparations for the treatment of [ cardiovascular disease, ] infectious diseases, and immunological, viral disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, July 1, 2011
Primary Code005
First Use Anywhere DateWednesday, May 19, 2004
First Use In Commerce DateWednesday, May 19, 2004

Trademark Owner History

Party NamePfizer Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Friday, July 1, 2011CANCELLED SEC. 8 (6-YR)
Friday, September 19, 2008CORRECTION UNDER SECTION 7 ¿ PROCESSED
Wednesday, July 9, 2008ASSIGNED TO PARALEGAL
Tuesday, June 3, 2008TEAS SECTION 7 REQUEST RECEIVED
Wednesday, February 27, 2008ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 27, 2008TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, June 21, 2007TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, November 30, 2004REGISTERED-PRINCIPAL REGISTER
Wednesday, September 29, 2004LAW OFFICE REGISTRATION REVIEW COMPLETED
Friday, September 24, 2004ASSIGNED TO LIE
Friday, September 24, 2004ASSIGNED TO LIE
Monday, September 20, 2004ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, September 9, 2004ASSIGNED TO EXAMINER
Monday, August 23, 2004STATEMENT OF USE PROCESSING COMPLETE
Monday, August 23, 2004USE AMENDMENT FILED
Thursday, August 26, 2004PAPER RECEIVED
Monday, August 23, 2004TEAS STATEMENT OF USE RECEIVED
Monday, August 23, 2004TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, April 16, 2004EXTENSION 3 GRANTED
Tuesday, April 6, 2004EXTENSION 3 FILED
Wednesday, April 14, 2004CASE FILE IN TICRS
Tuesday, April 6, 2004TEAS EXTENSION RECEIVED
Monday, September 22, 2003EXTENSION 2 GRANTED
Monday, September 22, 2003EXTENSION 2 FILED
Monday, September 22, 2003TEAS EXTENSION RECEIVED
Tuesday, June 10, 2003EXTENSION 1 GRANTED
Thursday, April 17, 2003EXTENSION 1 FILED
Thursday, April 17, 2003PAPER RECEIVED
Tuesday, October 22, 2002NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 30, 2002PUBLISHED FOR OPPOSITION
Wednesday, July 10, 2002NOTICE OF PUBLICATION
Monday, June 3, 2002APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, May 31, 2002ASSIGNED TO EXAMINER

Related Keywords

nuresca diseases immunological viral disorders infectious disease preparations treatment cardiovascular pharmaceutical